BRPI0516737A - método para tratamento ou prevenção da infecção pelo vìrus da hepatite c, usos de um derivado de ciclosporina e de 3-[(r) -2- (n,n-dimetilamino) etiltio-sar] -4- (gama-hidroximetileucina) ciclosporina, ou um sal farmaceuticamente aceitável deste, sal farmaceuticamente aceitável do derivado de ciclosporina, e, hidrato - Google Patents

método para tratamento ou prevenção da infecção pelo vìrus da hepatite c, usos de um derivado de ciclosporina e de 3-[(r) -2- (n,n-dimetilamino) etiltio-sar] -4- (gama-hidroximetileucina) ciclosporina, ou um sal farmaceuticamente aceitável deste, sal farmaceuticamente aceitável do derivado de ciclosporina, e, hidrato

Info

Publication number: BRPI0516737A
Authority: BR; Brazil
Prior art keywords: pharmaceutically acceptable; acceptable salt; cyclosporine; derivative; hydroxymethylucine
Prior art date: 2004-10-01

Application number

BRPI0516737-0A

Other languages

English (en)

Inventor

Hans Georg Fliri

David Renwick Houck

Original Assignee

Scynexis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-01

Filing date

2005-09-30

Publication date

2008-04-29

2005-09-30 Application filed by Scynexis Inc filed Critical Scynexis Inc

2008-04-29 Publication of BRPI0516737A publication Critical patent/BRPI0516737A/pt

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 4
150000003839 salts Chemical class 0.000 title 2
108010036949 Cyclosporine Proteins 0.000 title 1
229960001265 ciclosporin Drugs 0.000 title 1
229930182912 cyclosporin Natural products 0.000 title 1
208000010710 hepatitis C virus infection Diseases 0.000 title 1
241000711549 Hepacivirus C Species 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

BRPI0516737-0A 2004-10-01 2005-09-30 método para tratamento ou prevenção da infecção pelo vìrus da hepatite c, usos de um derivado de ciclosporina e de 3-[(r) -2- (n,n-dimetilamino) etiltio-sar] -4- (gama-hidroximetileucina) ciclosporina, ou um sal farmaceuticamente aceitável deste, sal farmaceuticamente aceitável do derivado de ciclosporina, e, hidrato BRPI0516737A (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US61515204P	2004-10-01	2004-10-01
US70762605P	2005-08-11	2005-08-11
PCT/US2005/035533 WO2006039668A2 (en)	2004-10-01	2005-09-30	3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection

Publications (1)

Publication Number	Publication Date
BRPI0516737A true BRPI0516737A (pt)	2008-04-29

Family

ID=36143148

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0516737-0A BRPI0516737A (pt)	2004-10-01	2005-09-30	método para tratamento ou prevenção da infecção pelo vìrus da hepatite c, usos de um derivado de ciclosporina e de 3-[(r) -2- (n,n-dimetilamino) etiltio-sar] -4- (gama-hidroximetileucina) ciclosporina, ou um sal farmaceuticamente aceitável deste, sal farmaceuticamente aceitável do derivado de ciclosporina, e, hidrato

Country Status (19)

Country	Link
US (2)	US20100167996A1 (pt)
EP (1)	EP1802650B1 (pt)
JP (2)	JP5139065B2 (pt)
KR (1)	KR101309409B1 (pt)
CN (1)	CN101773661B (pt)
AT (1)	ATE530561T1 (pt)
AU (1)	AU2005292162B2 (pt)
BR (1)	BRPI0516737A (pt)
CA (1)	CA2583494C (pt)
DK (1)	DK1802650T3 (pt)
ES (1)	ES2373450T3 (pt)
IL (1)	IL182315A (pt)
MX (1)	MX2007003538A (pt)
NZ (1)	NZ554514A (pt)
PL (1)	PL1802650T3 (pt)
PT (1)	PT1802650E (pt)
RU (1)	RU2399628C2 (pt)
SI (1)	SI1802650T1 (pt)
WO (1)	WO2006039668A2 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7196161B2 (en)	2004-10-01	2007-03-27	Scynexis Inc.	3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
ATE412005T1 (de)	2004-11-22	2008-11-15	Astellas Pharma Inc	Zyklosporinanalog
CN101316859A (zh)	2005-09-30	2008-12-03	西尼克斯公司	用于治疗和预防病毒感染的环孢菌素a的芳基烷基和杂芳基烷基衍生物
US7754685B2 (en)	2005-09-30	2010-07-13	Scynexis, Inc.	Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
PL1957518T3 (pl)	2005-10-26	2016-07-29	Astellas Pharma Inc	Nowe cykliczne związki peptydowe
NZ571826A (en)	2006-04-11	2012-01-12	Novartis Ag	HCV/HIV inhibitors and their uses
CA2652662C (en) *	2006-05-19	2015-11-03	Scynexis, Inc.	Methods for the treatment and prevention of ocular disorders
WO2007141395A1 (fr) *	2006-06-02	2007-12-13	Claude Annie Perrichon	Gestion des electrons actifs
SG175621A1 (en) *	2006-10-12	2011-11-28	Novartis Ag	Use of modified cyclosporins
US7576057B2 (en)	2006-11-20	2009-08-18	Scynexis, Inc.	Cyclic peptides
WO2008127613A1 (en) *	2007-04-11	2008-10-23	Scynexis, Inc.	New pharmaceutical compositions
CA2684557A1 (en)	2007-05-02	2008-11-20	Astellas Pharma Inc.	New cyclic peptide compounds
EP2280989B1 (en) *	2008-06-06	2016-02-10	Scynexis, Inc.	Cyclosporin analogs and their use in the treatment of hcv infections
WO2009148615A1 (en) *	2008-06-06	2009-12-10	Scynexis, Inc.	Cyclosporin analogs and their use in the treatment of hcv infections
MX2011001152A (es)	2008-07-30	2011-06-09	Isotechnika Pharma Inc	Moleculas de analogo de ciclosporina no-inmunesupresoras.
WO2010076329A1 (en)	2008-12-31	2010-07-08	Scynexis, Inc.	Derivatives of cyclosporin a
SG172848A1 (en) *	2009-01-07	2011-08-29	Scynexis Inc	Cyclosporine derivative for use in the treatment of hcv and hiv infection
WO2010088573A1 (en) *	2009-01-30	2010-08-05	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en)	2009-02-19	2013-07-09	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US20110182850A1 (en)	2009-04-10	2011-07-28	Trixi Brandl	Organic compounds and their uses
US8512690B2 (en)	2009-04-10	2013-08-20	Novartis Ag	Derivatised proline containing peptide compounds as protease inhibitors
US8685917B2 (en)	2009-07-09	2014-04-01	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8367053B2 (en)	2009-07-09	2013-02-05	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8349312B2 (en)	2009-07-09	2013-01-08	Enanta Pharmaceuticals, Inc.	Proline substituted cyclosporin analogues
EA201200650A1 (ru)	2009-10-30	2012-12-28	Бёрингер Ингельхайм Интернациональ Гмбх	Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
US20110144005A1 (en)	2009-12-09	2011-06-16	Scynexis, Inc.	Novel cyclic peptides
NZ599963A (en) *	2009-12-18	2014-02-28	Boehringer Ingelheim Int	Hcv combination therapy
KR20120125610A (ko)	2009-12-30	2012-11-16	싸이넥시스, 인크.	시클로스포린 유사체
US8623814B2 (en)	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
CN107007815A (zh)	2010-07-16	2017-08-04	美国科技环球有限公司	新颖的环孢霉素a衍生物在病毒感染的治疗和预防中的应用
WO2012021796A2 (en)	2010-08-12	2012-02-16	S&T Global, Inc.	Novel cyclosporin derivatives for the treatment and prevention of a viral infection
CA2811799A1 (en)	2010-10-08	2012-04-12	Novartis Ag	Vitamin e formulations of sulfamide ns3 inhibitors
US9890198B2 (en)	2010-12-03	2018-02-13	S&T Global Inc.	Cyclosporin derivatives and uses thereof
DK2646043T3 (da) *	2010-12-03	2017-05-22	S&T Global Inc	Hidtil ukendte cyclosporinderivater til behandling og forebyggelse af en virusinfektion
MY192981A (en)	2010-12-15	2022-09-20	Contravir Pharmaceuticals Inc	Cyclosporine analogue molecules modified at amino acid 1 and 3
RU2448690C1 (ru) *	2011-03-15	2012-04-27	Открытое акционерное общество "Биосинтез"	Твердая лекарственная форма пролонгированного действия нестероидного противовоспалительного средства кетопрофен, способ получения
CN103987399A (zh) *	2011-08-19	2014-08-13	美国科技环球有限公司	用于治疗和预防病毒感染的新型环孢菌素衍生物
AU2013267435B2 (en)	2012-06-01	2017-11-09	Allergan, Inc.	Cyclosporin A analogs
US8906853B2 (en)	2012-11-28	2014-12-09	Enanta Pharmaceuticals, Inc.	[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
US20140205566A1 (en)	2012-11-30	2014-07-24	Novartis Ag	Cyclic nucleuoside derivatives and uses thereof
KR20160045136A (ko) *	2013-08-26	2016-04-26	이난타 파마슈티칼스, 인코포레이티드	C형 간염을 예방 또는 치료하기 위한 사이클로스포린 유사체
WO2016073480A1 (en)	2014-11-03	2016-05-12	Enanta Pharmaceuticals, Inc.	Novel cyclosporin analogues for preventing or treating hepatitis c infection
TW201639873A (zh)	2015-01-08	2016-11-16	歐樂根公司	Ｍｅｂｍｔ側鏈已環化之環孢菌素衍生物
US10077289B2 (en)	2015-03-31	2018-09-18	Allergan, Inc.	Cyclosporins modified on the MeBmt sidechain by heterocyclic rings
WO2017004304A1 (en) *	2015-06-30	2017-01-05	Cypralis Limited	Novel macrocycles
GB201711749D0 (en) *	2017-07-21	2017-09-06	Cypralis Ltd	Cyclosporin analogues and uses thereof
WO2020037530A1 (en)	2018-08-22	2020-02-27	Waterstone Pharmaceuticals (Wuhan) Co., Ltd.	Crystalline form of compound and uses thereof in medicine
KR20220080181A (ko)	2019-10-12	2022-06-14	파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드	신독소-유도된 신장 손상의 치료 및 예방
CN115298199A (zh) *	2020-03-26	2022-11-04	睿诺医疗科技（上海）有限公司	环孢菌素衍生物的制备
CN113694177B (zh) *	2020-04-15	2022-06-17	睿诺医疗科技（上海）有限公司	器官损伤的预防和治疗

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0194972B1 (en) *	1985-03-11	1992-07-29	Sandoz Ag	Novel cyclosporins
US4814323A (en) *	1986-03-25	1989-03-21	Andrieu J M	Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
US4885276A (en) *	1987-06-03	1989-12-05	Merck & Co., Inc.	Cyclosporin analogs with modified "C-9 amino acids"
US4798823A (en) *	1987-06-03	1989-01-17	Merck & Co., Inc.	New cyclosporin analogs with modified "C-9 amino acids"
US4996193A (en) *	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine
US5294604A (en) *	1989-12-20	1994-03-15	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating ocular diseases by periocular administration of cyclosporine A or G
DE69124459T3 (de) *	1990-11-02	2001-05-31	Novartis Ag, Basel	Zyklosporine
EP0692487A1 (en) *	1993-03-31	1996-01-17	Tokyo Tanabe Company Limited	Cholestasis ameliorant
CA2167537A1 (en) *	1993-07-19	1995-02-02	Tsuneo Ozeki	Hepatitis c virus proliferation inhibitor
DK0756489T3 (da) *	1994-06-01	1999-12-06	Yuhan Corp	Cyclosporinholdigt præparat og fremgangsmåde til fremstillingen af dette
HUP9900405A3 (en) *	1995-07-17	2001-04-28	Scynexis Inc Durham	Cyclosporin derivatives with anti-hiv effect
JP3089350B2 (ja) *	1995-11-20	2000-09-18	ギルフォードファーマシューティカルズインコーポレイテッド	シクロフィリンロタマーゼ活性の阻害剤
FR2757521B1 (fr) *	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) *	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) *	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2762843B1 (fr) *	1997-04-30	1999-12-10	Rhone Poulenc Rorer Sa	Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
BR9911160A (pt) *	1998-06-12	2001-04-03	Chem Ag C	Ciclosporinas
FR2780061B1 (fr) *	1998-06-22	2001-09-07	Rhone Poulenc Rorer Sa	Nouveau procede de preparation de derives de cyclosporine
CN1218958C (zh) *	1998-07-01	2005-09-14	德比奥药物股份有限公司	活性范围改善的环孢菌素
US6254860B1 (en) *	1999-04-13	2001-07-03	Allergan Sales, Inc.	Ocular treatment using cyclosporin-A derivatives
US6521595B1 (en) *	1999-11-19	2003-02-18	Lg Chemical, Ltd.	Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
AU2001276988B2 (en) *	2000-07-21	2007-01-25	Dendreon Corporation	Peptides as NS3-serine protease inhibitors of hepatitis C virus
KR20040039622A (ko) *	2002-11-04	2004-05-12	주식회사 엘지생활건강	모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
US6987090B2 (en) *	2002-05-09	2006-01-17	Lg Household & Health Care Ltd.	Use of 3-position cyclosporin derivatives for hair growth
GB0320638D0 (en) *	2003-09-03	2003-10-01	Novartis Ag	Organic compounds
US7196161B2 (en) *	2004-10-01	2007-03-27	Scynexis Inc.	3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
CN101316859A (zh) *	2005-09-30	2008-12-03	西尼克斯公司	用于治疗和预防病毒感染的环孢菌素a的芳基烷基和杂芳基烷基衍生物
US7754685B2 (en) *	2005-09-30	2010-07-13	Scynexis, Inc.	Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
CA2652662C (en) *	2006-05-19	2015-11-03	Scynexis, Inc.	Methods for the treatment and prevention of ocular disorders
US7576057B2 (en) *	2006-11-20	2009-08-18	Scynexis, Inc.	Cyclic peptides
WO2008127613A1 (en) *	2007-04-11	2008-10-23	Scynexis, Inc.	New pharmaceutical compositions
EP2280989B1 (en) *	2008-06-06	2016-02-10	Scynexis, Inc.	Cyclosporin analogs and their use in the treatment of hcv infections
WO2009148615A1 (en) *	2008-06-06	2009-12-10	Scynexis, Inc.	Cyclosporin analogs and their use in the treatment of hcv infections
WO2010076329A1 (en) *	2008-12-31	2010-07-08	Scynexis, Inc.	Derivatives of cyclosporin a
SG172848A1 (en) *	2009-01-07	2011-08-29	Scynexis Inc	Cyclosporine derivative for use in the treatment of hcv and hiv infection
CA2748792A1 (en) *	2009-01-07	2010-07-15	Samuel Earl Hopkins	Combination of a cyclosporine derivative and nucleosides for treating hcv
US20110144005A1 (en) *	2009-12-09	2011-06-16	Scynexis, Inc.	Novel cyclic peptides

2005
- 2005-09-30 CA CA2583494A patent/CA2583494C/en not_active Expired - Fee Related
- 2005-09-30 CN CN2010100010787A patent/CN101773661B/zh not_active Expired - Fee Related
- 2005-09-30 AU AU2005292162A patent/AU2005292162B2/en not_active Ceased
- 2005-09-30 EP EP05815625A patent/EP1802650B1/en not_active Not-in-force
- 2005-09-30 ES ES05815625T patent/ES2373450T3/es active Active
- 2005-09-30 NZ NZ554514A patent/NZ554514A/en not_active IP Right Cessation
- 2005-09-30 BR BRPI0516737-0A patent/BRPI0516737A/pt not_active IP Right Cessation
- 2005-09-30 AT AT05815625T patent/ATE530561T1/de active
- 2005-09-30 KR KR1020077009820A patent/KR101309409B1/ko not_active Expired - Fee Related
- 2005-09-30 DK DK05815625.8T patent/DK1802650T3/da active
- 2005-09-30 RU RU2007116119/04A patent/RU2399628C2/ru not_active IP Right Cessation
- 2005-09-30 MX MX2007003538A patent/MX2007003538A/es active IP Right Grant
- 2005-09-30 SI SI200531452T patent/SI1802650T1/sl unknown
- 2005-09-30 JP JP2007534872A patent/JP5139065B2/ja not_active Expired - Fee Related
- 2005-09-30 WO PCT/US2005/035533 patent/WO2006039668A2/en active Application Filing
- 2005-09-30 PL PL05815625T patent/PL1802650T3/pl unknown
- 2005-09-30 PT PT05815625T patent/PT1802650E/pt unknown
2007
- 2007-03-29 IL IL182315A patent/IL182315A/en not_active IP Right Cessation
2009
- 2009-12-21 US US12/643,860 patent/US20100167996A1/en not_active Abandoned
2012
- 2012-05-08 JP JP2012106395A patent/JP2012167113A/ja active Pending
- 2012-06-20 US US13/528,165 patent/US20120264679A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20100167996A1 (en)	2010-07-01
US20120264679A1 (en)	2012-10-18
AU2005292162A1 (en)	2006-04-13
CN101773661B (zh)	2013-09-25
PT1802650E (pt)	2011-12-30
WO2006039668A3 (en)	2007-04-19
RU2007116119A (ru)	2008-11-10
WO2006039668A2 (en)	2006-04-13
ATE530561T1 (de)	2011-11-15
EP1802650B1 (en)	2011-10-26
PL1802650T3 (pl)	2012-04-30
MX2007003538A (es)	2008-01-16
NZ554514A (en)	2010-10-29
EP1802650A2 (en)	2007-07-04
RU2399628C2 (ru)	2010-09-20
CN101773661A (zh)	2010-07-14
JP2008514732A (ja)	2008-05-08
CA2583494A1 (en)	2006-04-13
IL182315A0 (en)	2007-07-24
JP5139065B2 (ja)	2013-02-06
KR101309409B1 (ko)	2013-09-23
AU2005292162B2 (en)	2011-11-10
ES2373450T3 (es)	2012-02-03
JP2012167113A (ja)	2012-09-06
SI1802650T1 (sl)	2012-03-30
DK1802650T3 (da)	2012-02-06
KR20070073841A (ko)	2007-07-10
EP1802650A4 (en)	2008-08-20
IL182315A (en)	2013-08-29
CA2583494C (en)	2014-01-21
WO2006039668B1 (en)	2007-05-31
HK1108703A1 (en)	2008-05-16

Publication	Publication Date	Title
BRPI0516737A (pt)	2008-04-29	método para tratamento ou prevenção da infecção pelo vìrus da hepatite c, usos de um derivado de ciclosporina e de 3-[(r) -2- (n,n-dimetilamino) etiltio-sar] -4- (gama-hidroximetileucina) ciclosporina, ou um sal farmaceuticamente aceitável deste, sal farmaceuticamente aceitável do derivado de ciclosporina, e, hidrato
WO2007041632A3 (en)	2007-12-13	Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
EA200971026A1 (ru)	2011-02-28	Новые макроциклические ингибиторы репликации вируса гепатита с
MY148690A (en)	2013-05-31	Novel macrocyclic inhibitors of hepatitis c virus replication
GB0612423D0 (en)	2006-08-02	Therapeutic agents
EA200901241A1 (ru)	2010-02-26	Соединения для лечения гепатита с
SE0402735D0 (sv)	2004-11-09	Novel compounds
EA200601467A1 (ru)	2007-06-29	Макроциклические соединения в качестве ингибиторов вирусной репликации
EA200700362A1 (ru)	2008-08-29	Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
PT1404347E (pt)	2006-05-31	Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
ATE514699T1 (de)	2011-07-15	Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
EA200971041A1 (ru)	2010-08-30	Новые пептидные ингибиторы репликации вируса гепатита с
WO2004074270A3 (en)	2004-12-23	Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
ATE551060T1 (de)	2012-04-15	Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
TW200615266A (en)	2006-05-16	Organic compounds
EA200970595A1 (ru)	2010-02-26	Производные замещенных индазолов, активные в качестве ингибиторов киназ
ATE411022T1 (de)	2008-10-15	Pyridylpyrrol-derivate als wirksame kinase-hemmer
WO2012142093A3 (en)	2013-02-07	2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
ATE498630T1 (de)	2011-03-15	Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
DK1427708T3 (da)	2008-11-24	Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme
WO2007024843A3 (en)	2007-08-09	Pyrimidinyl-pyrazole inhibitors of aurora kinases
EA200870577A1 (ru)	2009-06-30	Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
DE602004008959D1 (de)	2007-10-25	Benzoäbüä1,4üdioxepinderivate
WO2007077203A3 (en)	2007-08-30	Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
WO2006108682A3 (en)	2007-03-08	Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents

Legal Events

Date	Code	Title	Description
2012-04-10	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2015-07-28	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 10A ANUIDADE.
2015-11-24	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2325 DE 28-07-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.